Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
IRTC · against 259 other Healthcare companies of similar size
Ranked #200 of 260 · scores higher than 23% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 30–39, including IRTC · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | IRTC | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 255 reported | -0.3% | 2.5% | 30% | 30% | |
| EBITDA yieldHigher is better · 254 reported | 0.4% | 5.0% | 25% | 50% | |
| Free cash flow yieldHigher is better · 138 reported | 0.9% | 0.9% | 50% | 20% | |
| Book yieldHigher is better · 254 reported | 4.5% | 27.5% | 7% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 5 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 192 | 3.3B USD | 33 | 39 | |
| 197 | 3.0B CHF (≈$3.5B) | 32 | 33 | |
| 198 | 2.2B USD | 31 | 36 | |
| 198 | 3.1B USD | 31 | 46 | |
| 200 | 4.2B USD | 30 | 41 | |
| 200 | 4.7B USD | 30 | 42 | |
| 202 | 3.9B USD | 8 | 47 | |
| 202 | 7.7B USD | 8 | 36 | |
| 202 | 6.9B EUR (≈$7.6B) | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score